B. Metzler Seel. Sohn & Co. Ag Dyne Therapeutics, Inc. Transaction History

B. Metzler Seel. Sohn & Co. Ag

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$6.62 - $13.64 $6,547 - $13,489	989 Added 5.21%	19,962 $265,000
Q3 2023 Nov 13, 2023	SELL	$8.6 - $12.18 $163,167 - $231,091	-18,973 Reduced 50.0%	18,973 $169,000
Q2 2023 Aug 11, 2023	BUY	$8.53 - $14.28 $161,839 - $270,934	18,973 Added 100.0%	37,946 $426,000
Q1 2023 May 10, 2023	BUY	$10.88 - $15.0 $37,383 - $51,540	3,436 Added 22.11%	18,973 $218,000
Q4 2022 Feb 13, 2023	BUY	$9.37 - $13.8 $27,482 - $40,475	2,933 Added 23.27%	15,537 $180,000
Q3 2022 Nov 14, 2022	BUY	$7.2 - $15.17 $90,748 - $191,202	12,604 New	12,604 $160,000

209

102M

234K

238K

Ticker DYN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,765,400
Market Cap $1.24B
Description
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...

Get notified when there are updates to the investment portfolio of B. Metzler Seel. Sohn & Co. Ag, based on Form 13F filings with the SEC.

Stay updated on B. Metzler Seel. Sohn & Co. Ag with notifications on news.